Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DYN Stock Forecast 2026-2027
$20.41
Current Price
$3.37B
Market Cap
Buy 14
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to DYN Price Targets
+145.0%
To High Target of $50.00
+93.5%
To Median Target of $39.50
-21.6%
To Low Target of $16.00
DYN Price Momentum
+7.4%
1 Week Change
+16.2%
1 Month Change
+149.8%
1 Year Change
+4.3%
Year-to-Date Change
-18.4%
From 52W High of $25.00
+168.9%
From 52W Low of $7.59
📊 TOP ANALYST CALLS
Did DYN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dyne Therapeutics is one of their latest high-conviction picks.
Latest DYN Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, DYN has a bullish consensus with a median price target of $39.50 (ranging from $16.00 to $50.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $20.41, the median forecast implies a 93.5% upside. This outlook is supported by 14 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ananda Ghosh at HC Wainwright & Co., projecting a 145.0% upside. Conversely, the most conservative target is provided by Tessa Romero at JP Morgan, suggesting a 21.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DYN Analyst Ratings
14
Buy
2
Hold
0
Sell
DYN Price Target Range
Low
$16.00
Average
$39.50
High
$50.00
Current: $20.41
Latest DYN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DYN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $38.00 |
| Mar 3, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $38.00 |
| Mar 3, 2026 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $47.00 |
| Mar 3, 2026 | HC Wainwright & Co. | Ananda Ghosh | Buy | Maintains | $50.00 |
| Jan 20, 2026 | JP Morgan | Tessa Romero | Neutral | Maintains | $16.00 |
| Dec 15, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $36.00 |
| Dec 11, 2025 | Stifel | Paul Matteis | Buy | Maintains | $39.00 |
| Dec 10, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Upgrade | $40.00 |
| Dec 9, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $38.00 |
| Dec 9, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $50.00 |
| Dec 8, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Maintains | $60.00 |
| Nov 14, 2025 | JP Morgan | Tessa Romero | Neutral | Maintains | $17.00 |
| Nov 12, 2025 | Oppenheimer | Andreas Argyrides | Perform | Maintains | $11.00 |
| Nov 6, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $30.00 |
| Nov 6, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Maintains | $46.00 |
| Oct 10, 2025 | Oppenheimer | Andreas Argyrides | Perform | Downgrade | $13.00 |
| Aug 25, 2025 | Raymond James | Martin Auster | Strong Buy | Upgrade | $35.00 |
| Aug 6, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $13.00 |
| Jul 31, 2025 | Stifel | Paul Matteis | Buy | Maintains | $36.00 |
| Jul 29, 2025 | Raymond James | Martin Auster | Outperform | Reiterates | $31.00 |
Dyne Therapeutics Inc. (DYN) Competitors
The following stocks are similar to Dyne Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DYN
Dyne Therapeutics
mkt cap
3.37B
Dyne Therapeutics Inc. (DYN) Financial Data
Valuation Metrics
Market Cap
$3.37B
Enterprise Value
$2.43B
P/E Ratio
N/A
PEG Ratio
-6.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.0%
Current Ratio
22.3x
Debt/Equity
17.4x
ROE
-55.7%
ROA
-31.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dyne Therapeutics Inc. (DYN) Business Model
About Dyne Therapeutics Inc.
What They Do
Develops therapies for neuromuscular diseases.
Business Model
Dyne Therapeutics operates as a clinical-stage biopharmaceutical company that generates revenue by advancing innovative RNA therapies through clinical development towards regulatory approval and potential commercialization. The company focuses on genetically driven neuromuscular diseases, leveraging its proprietary FORCE platform to improve delivery to muscle tissue and the central nervous system.
Additional Information
Dyne's lead programs target significant unmet needs in conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. By addressing rare diseases with limited treatment options, Dyne positions itself for potential market entry as its pipeline matures.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
258
CEO
Mr. John G. Cox M.B.A.
Country
United States
IPO Year
1993
Website
www.dyne-tx.comDyne Therapeutics Inc. (DYN) Latest News & Analysis
Latest News
Quick Summary
A poster presents positive results from the DELIVER clinical trial for Duchenne muscular dystrophy, highlighting clinical measures of functional improvement for managed care experts.
Why It Matters
Positive DELIVER trial results may enhance investor confidence in the company's DMD treatment, potentially leading to increased market share and revenue in the rare disease sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyne Therapeutics, Inc. (DYN) presented at the TD Cowen 46th Annual Health Care Conference, outlining key updates and insights into their business strategies and developments.
Why It Matters
Dyne Therapeutics' presentation at a major healthcare conference can influence investor sentiment by showcasing its progress, pipeline developments, and potential market opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Dyne Therapeutics has a solid $1.1B cash reserve to fund operations through mid-2028. Positive DELIVER trial results for DYNE-251 and the start of the Phase 3 HARMONIA trial for DYNE-101 are key developments.
Why It Matters
Dyne Therapeutics' strong cash position ensures operational stability, while positive trial data and a pivotal Phase 3 trial initiation could significantly boost future valuations.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Dyne Therapeutics reported positive 24-month results from the Phase 1/2 DELIVER trial for z-rostudirsen, showing improved heart and lung function in DMD patients compared to expected declines.
Why It Matters
Positive trial results for z-rostudirsen indicate potential for improved heart and lung function in DMD patients, enhancing Dyne Therapeutics' prospects and possibly boosting stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyne Therapeutics has launched the Phase 3 HARMONIA trial for z-basivarsen in myotonic dystrophy type 1, enrolling 150 participants to assess efficacy and safety, aligned with FDA guidelines.
Why It Matters
The HARMONIA trial's focus on z-basivarsen could lead to FDA approval, impacting Dyne Therapeutics' stock value and potential market position in neuromuscular therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
1 month ago
Quick Summary
Palo Alto Investors increased its stake in Dyne Therapeutics by 209,523 shares, now holding 1,472,197 shares valued at $28.80 million, representing 4.01% of its AUM.
Why It Matters
The increase in Dyne Therapeutics shares and significant valuation rise suggests growing investor confidence, potentially impacting stock price and attracting further interest in the company.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About DYN Stock
What is Dyne Therapeutics Inc.'s (DYN) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Dyne Therapeutics Inc. (DYN) has a median price target of $39.50. The highest price target is $50.00 and the lowest is $16.00.
Is DYN stock a good investment in 2026?
According to current analyst ratings, DYN has 14 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DYN stock?
Wall Street analysts predict DYN stock could reach $39.50 in the next 12 months. This represents a 93.5% increase from the current price of $20.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dyne Therapeutics Inc.'s business model?
Dyne Therapeutics operates as a clinical-stage biopharmaceutical company that generates revenue by advancing innovative RNA therapies through clinical development towards regulatory approval and potential commercialization. The company focuses on genetically driven neuromuscular diseases, leveraging its proprietary FORCE platform to improve delivery to muscle tissue and the central nervous system.
What is the highest forecasted price for DYN Dyne Therapeutics Inc.?
The highest price target for DYN is $50.00 from Ananda Ghosh at HC Wainwright & Co., which represents a 145.0% increase from the current price of $20.41.
What is the lowest forecasted price for DYN Dyne Therapeutics Inc.?
The lowest price target for DYN is $16.00 from Tessa Romero at JP Morgan, which represents a -21.6% decrease from the current price of $20.41.
What is the overall DYN consensus from analysts for Dyne Therapeutics Inc.?
The overall analyst consensus for DYN is bullish. Out of 21 Wall Street analysts, 14 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $39.50.
How accurate are DYN stock price projections?
Stock price projections, including those for Dyne Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 1:02 PM UTC